SigTuple vs Abridge
In-depth comparison — valuation, funding, investors, founders & more
🇮🇳 India · Rohit Kumar Pandey
Valuation
N/A
Total Funding
$20M
100-500 employees
🇺🇸 United States · Shiv Rao
Valuation
$850M
Total Funding
$150M
120 employees
Analyst Summary
Generated from real data · No AI hallucinations
Both SigTuple and Abridge compete directly in the AI Healthcare space, making this a head-to-head matchup within the same market segment. SigTuple develops AI-powered automated pathology solutions that digitize and analyze microscopy slides for blood, urine, sputum, and semen samples, enabling high-throughput diagnostic testing without the constant presence of trained pathologists. Abridge is an AI health company founded in 2018 that develops clinical documentation and conversation intelligence tools for healthcare providers.
Abridge carries a known valuation of $850M, while SigTuple's valuation has not been publicly disclosed. On the funding side, Abridge has raised $150M in total — $130M more than SigTuple's $20M.
SigTuple has 3 years more market experience, having been founded in 2015 compared to Abridge's 2018 founding. Both companies are currently at the Series B stage of their journey.
SigTuple operates out of 🇮🇳 India while Abridge is based in 🇺🇸 United States, giving each a distinct home-market advantage. On Awaira's 0–100 composite score, Abridge leads with a score of 76, reflecting stronger overall fundamentals across valuation, funding, and growth signals.
Metrics Comparison
| Metric | SigTuple | Abridge |
|---|---|---|
💰Valuation | N/A | $850M |
📈Total Funding | $20M | $150MWINS |
📅Founded | 2015 | 2018WINS |
🚀Stage | Series B | Series B |
👥Employees | 100-500 | 120 |
🌍Country | India | United States |
🏷️Category | AI Healthcare | AI Healthcare |
⭐Awaira Score | 60 | 76WINS |
Key Differences
Funding gap: Abridge has raised $130M more ($150M vs $20M)
Market experience: SigTuple has 3 years more (founded 2015 vs 2018)
Team size: SigTuple has 100-500 employees vs Abridge's 120
Market base: 🇮🇳 SigTuple (India) vs 🇺🇸 Abridge (United States)
Direct competitors: Both operate in the AI Healthcare market segment
Awaira Score: Abridge scores 76/100 vs SigTuple's 60/100
Which Should You Choose?
Use these signals to make the right call
Choose SigTuple if…
- ✓More market experience — founded in 2015
- ✓India-based for regional compliance or proximity
- ✓SigTuple develops AI-powered automated pathology solutions that digitize and analyze microscopy slides for blood, urine, sputum, and semen samples, enabling high-throughput diagnostic testing without the constant presence of trained pathologists
Choose Abridge if…
Top Pick- ✓Higher Awaira Score — 76/100 vs 60/100
- ✓More established by valuation ($850M)
- ✓Stronger investor backing — raised $150M
- ✓United States-based for regional compliance or proximity
- ✓Abridge is an AI health company founded in 2018 that develops clinical documentation and conversation intelligence tools for healthcare providers
Funding History
SigTuple raised $20M across 0 rounds. Abridge raised $150M across 5 rounds.
SigTuple
No public funding data available.
Abridge
Series B
Jan 2023
Series B
Jan 2022
Series A
Jun 2021
Lead: Kleiner Perkins
Series A
Jan 2021
Seed
Jan 2019
Investor Comparison
No shared investors detected between these two companies.
Unique to Abridge